A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study. Ivosidenib, or AG-120, is currently used against cancers that have a ...

We think that Ivosidenib, previously called AG-120, may be applicable to the large majority of cancers–the one percent with mutant IDH1 and the remaining 99% with wild-type IDH1." ...

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 2023;29:615-622.

In a separate report at SNO, long-term follow-up from a phase I study of perioperative therapy showed promising results with vorasidenib and the IDH1 inhibitor ivosidenib (Tibsovo) in diffuse IDH1 ...

The FDA approved ivosidenib for treatment of certain adults with relapsed or refractory myelodysplastic syndromes.The indication applies to use of the agent in adults who harbor susceptible ...

The arrival of Ivosidenib brings a ray of hope for those with the IDH1 mutation. These drugs are changing the paradigm of AML care, offering new hope where conventional therapy might fail or be ...

A new report is shedding light on how some patients with cholangiocarcinoma develop resistance to the mutant IDH1 inhibitor ivosidenib (Tibsovo), and how drug developers might be able to help ...

The Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of adults with previously treated locally advanced or metastatic IDH1-mutated cholangiocarcinoma (CCA), a ...

The FDA announced several regulatory actions the past few weeks. Here is an overview of decisions that may be relevant to your practice. The FDA granted priority review to ivosidenib tablets for ...

The US Food and Drug Administration (FDA) has approved tablets of ivosidenib (Tibsovo, Servier Pharmaceuticals) for adults with isocitrate dehydrogenase (IDH)-1 mutated relapsed or refractory ...